Increased Expression of Collagen XVIII and Its Prognostic Value in Nonsmall Cell Lung Carcinoma

Cancer

Volumn 100, Issue 8, 2004, Pages 1665-1672

  Chang, Hao ^a   Iizasa, Toshihiko ^a   Shibuya, Kiyoshi ^a   Iyoda, Akira ^a   Suzuki, Makoto ^a   Moriya, Yasumitsu ^a   Liu, Tian Ling ^a   Hiwasa, Takaki ^a   Hiroshima, Kenzo ^a   Fujisawa, Takehiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Collagen XVIII; Endostatin; Nonsmall cell lung carcinoma; Prognosis

Indexed keywords

COLLAGEN TYPE 18; ENDOSTATIN; TUMOR MARKER;

ADULT; ANGIOGENESIS; ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; COLLAGEN TYPE XVIII; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PROCOLLAGEN; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 11144358348     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20156     Document Type: Article

References (52)

1. Gridelli C, Rossi A, Maione P. Treatment of non-small cell lung cancer: state of the art and development of new biologic agents. Oncogene. 2003;22:6629-6638.
2. Okuno SH, Jett JR. Small cell lung cancer: current therapy and promising new regimens. Oncologist. 2002;7:234-238.
3. Le Chevalier T. Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2003;21(23 Suppl):238.
4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 2000;50:7-33.
5. Fielding LP, Fenoglio-Preiser CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer. 1992;70:2367-2377.
6. Mountain CF. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest. 1995;108:246-254.
7. Niklinski J, Furman M. Clinical tumor markers in lung cancer. Eur J Cancer Prev. 1995;4:129-138.
8. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small cell lung cancer. Br J Cancer. 1997;75:1125-1130.
9. Khuri FR, Lotan R, Kemp BL, et al. Retinoic acid receptor-beta as a prognostic indicator in Stage I non-small-cell lung cancer. J Clin Oncol. 2000;18:2798-2804.
10. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in Stage I non-small cell lung cancer. Clin Cancer Res. 2001;7:861-867.
11. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
12. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995;147:9-19.
13. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
14. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
15. Tanigawa N, Amaya H, Matrumura M, et al. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res. 1996;56:2671-2676.
16. Ogawa Y, Chung YS, Nakata B, et al. Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer. 1995;71:1297-1301.
17. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metatasis of non-small cell lung cancer. Lancet. 1992;18:145-146.
18. Yamazaki K, Abe S, Takekawa H, et al. Tumor angiogenesis in human lung adenocarcinoma. Cancer. 1994;74:2245-2250.
19. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
20. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:227-285.
21. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 1999;59:6052-6056.
22. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000;19:1187-1194.
23. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 1998;17:4249-4256.
24. Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol. 1997;16:319-328.
25. Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol. 1998;153:611-626.
26. Musso O, Rehn M, Saarela J, et al. Collagen XVIII is localized in sinusoids and basement membrane zones and expressed by hepatocytes and activated stellate cells in fibrotic human liver. Hepatology. 1998;28:98-107.
27. Marneros AG, Olsen BR. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 2001;20:337-345.
28. Suzuki M, Iizasa T, Ko E, et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer. 2002;35:29-34.
29. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
30. Kato H. Classification of lung cancer (1st English edition). Tokyo: Kanehara & Co., 2000.
31. Hiwasa T, Arase Y, Kikuno K, et al. Increase in ultraviolet sensitivity by overexpression of calpastatin in ultraviolet-resistant UVr-1 cells derived from ultraviolet- sensitive human RSa cells. Cell Death Differ. 2000;7:531-537.
32. Folkman J. Angiogenesis research: from laboratory to clinic. Forum (Genova). 1999;9:59-62.
33. Feldman AL, Restifo NP, Alexander HR, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin level in mice. Cancer Res. 2000;60:1503-1506.
34. Feldman AL, Alexander HR, Hewitt SM, et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst. 2001;93:1014-1020.
35. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-407.
36. Yamguchi N, Anand-Apte B, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999;18:4414-4423.
37. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999;274:11721-11726.
38. Eder JP Jr., Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002;20:3772-3784.
39. Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: a Phase I clinical trial with endostatin. Clin Cancer Res. 2001;7:3366-3374.
40. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002;20:3792-3803.
41. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-3814.
42. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003;21:223-231.
43. Rehn M, Pihlajaniemi T. Identification of three N-terminal ends of Type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. J Biol Chem. 1995;270:4705-4711.
44. Kuroi K, Tanaka C, Toi M. Circulating levels of endostatin in cancer patients. Oncol Rep. 2001;8:405-409.
45. Feldman AL, Tamarkin L, Paciotti GF, et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with Stage IV clear cell renal cancer. Clin Cancer Res. 2000;6:4628-4634.
46. Feldman AL, Pak H, Yang JC, Alexander HR Jr., Libutti SK. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer. 2001;91:1525-1529.
47. Homer JJ, Greenman J, Stafford ND. Circulating angiogenic cytokines as tumor markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol. 2002;27:32-37.
48. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer. 2003;97:2767-2775.
49. Jefferson MF, Pendleton N, Faragher EB, Dixon GR, Myskow MW, Horan MA. 'Tumor volume' as a predictor of survival after resection of non-small cell lung cancer (NSCLC). Br J Cancer. 1996;74:456-459.
50. Olsen BR. Life without perlecan has its problems. J Cell Biol. 1999;147:909-912.
51. Nikitakis NG, Rivera H, Lopes MA, et al. Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes. Am J Clin Pathol. 2003;119:574-586.
52. Musso O, Rehn M, Theret N, et al. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res. 2001;61:45-49.